Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2024-05-13 Earnings Release
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2024, reporting the results of operations and financial condition for the first quarter ended March 31, 2024. It specifically states that a press release announcing the financial results is furnished as an exhibit. The document itself is short (3700 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the 'Menu vs Meal' rule, such a document is an announcement of the earnings release, not the earnings release itself. Therefore, the correct classification is Earnings Release (ER).
2024-05-13 English
4
Director's Dealing
2024-05-03 English
3
Director's Dealing
2024-05-02 English
ARS
Annual Report
2024-04-30 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the upcoming Annual Meeting, voting instructions, and proposals to be voted on, such as election of directors and ratification of auditors. The document is titled 'Definitive Additional Materials' related to the proxy statement and contains no financial statements or detailed management discussion. It is not the proxy statement itself but additional materials related to it. Given the content and the form type, this fits best under Remuneration Information (DEF 14A), which covers proxy statements and related materials detailing compensation and governance matters for shareholders' votes.
2024-04-30 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.